A multicentre single blind randomised controlled Phase-II/III study to evaluate immunogenicity and safety of single intramuscular dose of Biological E's Vi-capsular Polysaccharide-CRM197 Conjugate Typhoid Vaccine in healthy infants, children and adults in comparison with a licensed comparator.
Latest Information Update: 12 Nov 2019
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Typhoid
- Focus Pharmacodynamics
- Sponsors Biological E Limited
Most Recent Events
- 05 Nov 2019 Status changed from recruiting to completed.
- 25 Mar 2019 New trial record